Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cardiovascular Disorders
Published in: BMC Cardiovascular Disorders 1/2018

Open Access 01-12-2018 | Correspondence

Deleterious effects of catecholamine administration in acute heart failure caused by unrecognized Takotsubo cardiomyopathy

Authors: Michael Dandel, Roland Hetzer

Published in: BMC Cardiovascular Disorders | Issue 1/2018

Login to get access

Abstract

The potential life-threatening consequences of catecholamine use for emergency circulatory support in Takotsubo cardiomyopathy-related acute heart failure is a major challenge in cardiovascular emergences. In their recent work in BMC Cardiovascular Disorders Ansari U. et al. demonstrated the harmful effects of catecholamines on the outcome of patients with Takotsubo cardiomyopathy. Concerning this matter we emphasize the usefulness of speckle-tracking-derived echocardiography for early recognition of an acute phase of a Takotsubo syndrome in order to avoid the deleterious effects of a catecholamine therapy in patients with Takotsubo-associated acute heart failure.
Literature
1.
Ansari U, El-Battrawy I, Fastner C, et al. Clinical outcomes associated with catecholamine use in patients diagnosed with Takotsubo cardiomyopathy. BMC Cardiovasc Disord. 2018;18(1):54.CrossRefPubMedPubMedCentral
2.
Akashi YJ, Nakazawa K, Sakakibara M, et al. The clinical features of takotsubo cardiomyopathy. QJM. 2003;96(8):563–73.CrossRefPubMed
3.
Borchert T, Hübscher D, Guessoum CI, et al. Catecholamine-dependent β-adrenergic signaling in a pluripotent stem cell model of TakotsuboCardiomyopathy. J Am Coll Cardiol. 2017;70(8):975–91.CrossRefPubMed
4.
Dandel M, Lehmkuhl HB, Schmidt G, et al. Striking observations during emergency catecholamine treatment of cardiac syncope in a patient with initially unrecognized Takotsubo cardiomyopathy. Circ J. 2009;73:1543–6.CrossRefPubMed
5.
Dandel M, Lehmkuhl H, Knosalla C, Hetzer R. Left ventricular wall motion abnormality and myocardial dysfunction in stress cardiomyopathy: new pathophysiological aspects suggested by echocardiography. Int J Cardiol. 2009;135(2):40–3.CrossRef
6.
Sharkey SW, Lesser JR, Zenovich AG, Maron MS, Lindberg J, Longe TF, et al. Acute and reversible cardiomyopathy provoked by stress in women from the United States. Circulation. 2005;111:472–9.CrossRefPubMed
7.
Merli E, Sutcliffe S, Gori M, Sutherland GG. Tako-Tsubo cardiomyopathy: new insights into the possible underlying pathophysiology. Eur J Echocardiogr. 2006;7:53–61.CrossRefPubMed
8.
Akashi YJ, Tejima T, Sakurada H, Matsuda H, Suzuki K, Kawasaki K, et al. Left ventricular rupture with Takotsubo cardiomyopathy. Mayo Clin Proc. 2004;79:821–4.CrossRefPubMed
Metadata
Title
Deleterious effects of catecholamine administration in acute heart failure caused by unrecognized Takotsubo cardiomyopathy
Authors
Michael Dandel
Roland Hetzer
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2018
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-018-0882-5

Other articles of this Issue 1/2018

BMC Cardiovascular Disorders 1/2018 Go to the issue

Research article

Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis

Research article

Homocysteine is a bystander for ST-segment elevation myocardial infarction: a case-control study

Research article

Whole-exome sequencing identifies R1279X of MYH6 gene to be associated with congenital heart disease

Research article

Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target

Study protocol

A Personal Decision Support System for Heart Failure Management (HeartMan): study protocol of the HeartMan randomized controlled trial

Research article

Early commitment of cardiovascular autonomic modulation in Brazilian patients with congenital generalized lipodystrophy

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits